Morningstar

Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)

A multicenter, multinational Phase 3 Casppian study will evaluate the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release in patients with CPP. Gonadotropin-releasing hormone ...
Yahoo Finance

Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)

The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring ...
MedPage Today

Breastfeeding May Protect Against Early Puberty

Exclusive breastfeeding was associated with a lower risk of central precocious puberty (CPP) in boys and girls. CPP has been linked with an increased risk of adult health problems, like diabetes, ...
Medindia

Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)

TAIPEI, Feb. 4, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces the fourth positive safety review by the independent Data and Safety Monitoring Board for its ...
Pharmabiz

Foresee Pharma gets fourth positive recommendation from DSMB to continue the Casppian Ph3 study, for central precocious puberty

Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company, announces the fourth positive safety review by the independent Data and Safety Monitoring Board for its Casppian phase 3 ...